AU Patent

AU2015269412B2 — Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications

Assigned to Exicure Operating Co · Expires 2020-03-12 · 6y expired

What this patent protects

Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.

USPTO Abstract

Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015269412B2
Jurisdiction
AU
Classification
Expires
2020-03-12
Drug substance claim
No
Drug product claim
No
Assignee
Exicure Operating Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.